| octreotide acetate / Generic mfg. |
| Completed | 4 | 45 | | 0.9%saline muscular injection monthly ;20mg long-acting octreotide muscular injection mon ;40mg long-acting octreotide muscular injection mon | Shanghai Sixth People's Hospital; Shanghai Sixth People's Hospital, none | portal hypertension | | | | |
ChiCTR-TRC-14004384: Long-acting Octreotide Prevents Variceal Rebleeding in Patients with Portal Hypertension |
|
|
| Completed | 4 | 75 | | 0.9%saline muscular injection monthly ;20mg long-acting octreotide muscular injection monthly ;40mg long-acting octreotide muscular injection monthly | Shanghai Sixth People's Hospital; Level of the institution：, self-funding | liver cirrosis, portal hypertension | | | | |
| Ongoing | 4 | 30 | Europe | Octreotide, SMS995, Sandostatine 0,1 mg/ml, Sandostatine LAR 20 mg, Sandostatine 0,1 mg/ml, Sandostatine LAR 20 mg | UZ LEUVEN | Dumping Syndrome is a condition characterized by weakness, dizziness, flushing and warmth, nausea and palpitation immediately or shortly after eating and produced by abnormally rapid emptying of the stomach in persons who have had part of the stomach removed or in hypersensitive or neurotic individuals | | | | |
2009-017849-57: Somatostatin analogues as a volume reducing treatment of polycystic livers |
|
|
| Ongoing | 4 | 50 | Europe | Sandostatin LAR, Somatuline Autosolution, unknown, | Radboud University Nijmegen Medical Centre | Polycystic liver disease, due to isolated polycystic liver disease or polycystic kidney disease. | | | | |
| Ongoing | 4 | 100 | Europe | Somatuline Autogel, Sandostatin LAR, Dostinex, Somavert, Somatuline Autogel, Sandostatin LAR, Dostinex, Somavert | Österreichisches Akromegalie Register, Österreichisches Akromegalieregister | Acromegaly | | | | |
2014-003856-30: Trial for patients with neuro-endocrine tumors with carcinoid syndrome receiving octreotide LAR. |
|
|
| Ongoing | 4 | 50 | Europe | SANDOSTATIN LAR, Injection, Sandostatine Long Acting Repeatable (LAR) 10, 20, 30 mg | Cliniques Universitaires Saint Luc, Cliniques Universitaires Saint Luc, Novartis pharma SA/NV | The primary objective is to observe the change from baseline in the incidence of diarrhea and flushing in correlation to the serum octreotide level, independently of the dose variations of octreotide LAR., To observe the change from baseline in the incidence of diarrhea and flushing in relation to the serum octreotide level (level in the blood) independently of the dose variations of octreotide LAR., Diseases [C] - Cancer [C04] | | | | |
NCT03289741: A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide |
|
|
| Completed | 4 | 53 | US | Octreotide, LAR Lanreotide, Questionnaires | Memorial Sloan Kettering Cancer Center | Neuroendocrine Tumors | 04/23 | 04/23 | | |
| Recruiting | 4 | 100 | | Long acting octreotide 20mg/30mg injection was given every 28 days for 12 months ;Follow-up observation | Cancer Hospital Chinese Academy of Medical Sciences; Cancer Hospital Chinese Academy of Medical Sciences, Self-funded | Neuroendocrine Tumors | | | | |
CTR20221314: To compare the safety and efficacy of lutetium [177Lu] oxyoctreotide injection versus long-acting octreotide in patients with inoperable or metastatic, progressive, well-differentiated (G1 and G2), somatostatin receptor-positive gastroenteropancreatic neu |
|
|
| Ongoing | 3 | 213 | China | octreotide acetate solution for injection - Generic mfg. | Beijing Xiantong International Pharmaceutical Technology Co., Ltd | Unresectable or metastatic, progressive, well-differentiated (G1 and G2) and somatostatin receptor-positive adult patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). | | | | |
SWOG-S0518, NCT00569127: Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor |
|
|
| Active, not recruiting | 3 | 427 | US | Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, CT-P16, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Laboratory Biomarker Analysis, Octreotide Acetate, D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hyroxymethyl)propyl]-L-cysteinamide, Cyclic (2->7)-disulfide, Acetate (Salt), Longastatin, Longastatina, Samilstin, Sandostatin, Sandostatin LAR, Sandostatin Lar Depot, Sandostatina, Sandostatine, SMS 201-995, SMS 201-995 AC, Recombinant Interferon Alfa-2b, Alfatronol, Glucoferon, Heberon Alfa, IFN alpha-2B, Interferon alfa 2b, Interferon Alfa-2B, Interferon Alpha-2b, Intron A, Sch 30500, Urifron, Viraferon | National Cancer Institute (NCI) | Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1, Neuroendocrine Neoplasm, Neuroendocrine Tumor, Neuroendocrine Tumor G2 | 01/15 | 01/25 | | |
2014-004032-19: The effectiveness of the drug octreotide to anemia in patients with small bowel bleeding due to vascualr malformations. |
|
|
| Ongoing | 3 | 62 | Europe | Sandostatin LAR, RVG 18236, Sandostatin LAR 20 mg, Sandostatin LAR 20 mg | Radboud University Medical Center, Radboud University Medical Center | small bowel angiodysplasias | | | | |
2022-000507-12: A randomized, controlled, open-label study of RYZ101 compared with standard of care therapy in subjects with inoperable, advanced, SSTR+ well-differentiated GEP-NET that has progressed following 177Lu SSA therapy Ensayo aleatorizado, controlado y abierto de RYZ101 frente al tratamiento habitual en sujetos con tumores neuroendocrinos gastroenteropancreáticos bien diferenciados SSTR+, avanzados e inoperables, que hayan progresado tras tratamiento con 177Lu SSA. |
|
|
| Not yet recruiting | 3 | 288 | Europe | RYZ101, Sunitinib, RYZ101, Sunitinib, L01XE04, Solution for injection, Tablet, Capsule, hard, Powder and solvent for suspension for injection, Solution for injection in pre-filled syringe, Everolimus Zentiva 5mg Tabletten, Szunitinib Mylan 12,5 mg, Sandostatin® LAR®- Monatsdepot 30 mg powder and solvent for suspension for injection, SOMATULINE AUTOGEL 120 mg solution for injection in a pre-filled syringe, Szunitinib Sandoz 12,5 mg | RayzeBio, Inc., RayzeBio, Inc. | gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) Tumores neuroendocrinos gastroenteropancreáticos, gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) Tumores neuroendocrinos gastroenteropancreáticos, Diseases [C] - Cancer [C04] | | | | |
| Active, not recruiting | 3 | 226 | Europe, Canada, US, RoW | Lutathera, long-acting octreotide, high dose long-acting octreotide, Optional post-progression re-treatment with Lutathera, Optional post-progression cross-over to Lutathera, Optional post-progression re-treatment with Lutathera after cross-over | Advanced Accelerator Applications | Gastro-enteropancreatic Neuroendocrine Tumor | 07/23 | 10/27 | | |
| Active, not recruiting | 3 | 332 | Europe, Canada, US, RoW | CAM2029, Octreotide LAR, Lanreotide ATG | Camurus AB | Gastro-enteropancreatic Neuroendocrine Tumor | 12/24 | 12/26 | | |
NCT05459844: A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs |
|
|
| Recruiting | 3 | 196 | RoW | Lutetium[177Lu] Oxodotreotide Injection, 177Lu-DOTA0-Tyr3-Octreotate, Octreotide LAR, SANDOSTATIN LAR, Octreotide | Sinotau Pharmaceutical Group | Neuroendocrine Tumors | 12/24 | 12/28 | | |
ACTION-1, NCT05477576: Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy |
|
|
| Active, not recruiting | 3 | 288 | Europe, Canada, US, RoW | RYZ101, Everolimus 10 mg, Sunitinib 37.5 MG, Octreotide LAR 60 MG Injection, Lanreotide 120Mg Sa Susp Inj Syringe | RayzeBio, Inc. | GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET | 07/25 | 07/28 | | |
NCT05884255: An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors. |
|
|
| Recruiting | 3 | 220 | RoW | Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide, long-acting Octreotide. | Jiangsu HengRui Medicine Co., Ltd. | Advanced Gastroenteropancreatic Neuroendocrine Tumor | 12/26 | 10/30 | | |
NCT01744249 / 2011-001550-29: Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas |
|
|
| Active, not recruiting | 2/3 | 255 | Europe | Axitinib, Sandostatin LAR, Placebo | Grupo Espanol de Tumores Neuroendocrinos, Pfizer | Neuroendocrine Tumors, Advanced Cancer | 08/21 | 10/21 | | |
| Active, not recruiting | 2 | 60 | | | Site - Investigator Initiated, Novartis Educational Grant | Advanced Hepatocellular Carcinoma | | | | |
2006-001150-27: Sandostatin LAR in prevention of Chemotherapy Induced Diarrhea |
|
|
| Ongoing | 2 | 25 | Europe | Sandostatin LAR, Powder for suspension for injection, Sandostatine Long Acting Repeatable | University Hospital Gent | Chemo-Therapy Induced Diarrhea | | | | |
2014-000888-41: Activity and safety of Everolimus in combination with octreotide LAR and Metformin in patients with advanced pancreatic well-differentiated Neuroendocrine Tumors (pWDNETs): a Phase II, open, monocentric, prospective study. VALUTAZIONE DELL’ATTIVITÀ E DELLA SICUREZZA DELLA COMBINAZIONE EVEROLIMUS, OCTREOTIDE LAR E METFORMINA IN PAZIENTI AFFETTI DA TUMORI NEUROENDOCRINI DEL PANCREAS BEN DIFFERENZIATI IN STADIO AVANZATO E/O NON RESECABILI. STUDIO CLINICO-BIOLOGICO DI FASE II, MetNET 1 Trial. |
|
|
| Not yet recruiting | 2 | 43 | Europe | Afinitor, Sandostatina lar 30, Metformina teva, 039398045, Tablet, Injection, Afinitor, Sandostatina lar 30, Metformina teva | Fondazione IRCCS Istituto Nazionale dei tumori, Not applicable | advanced/ or not resectable well differnciated pancreatic neuroendocrin tumor Tumore neuroendocrino del pancreas ben differenziato avanzato e/o non resecabile, advanced/ or not resectable well differnciated pancreatic neuroendocrin tumor Tumore neuroendocrino del pancreas ben differenziato avanzato e/o non resecabile, Diseases [C] - Cancer [C04] | | | | |
2008-007153-13: An open label, single arm, phase II study of combination RAD001 and octreotide LAR in patients with advanced neuroendocrine tumors as first line treatment |
|
|
| Ongoing | 2 | 50 | Europe | EVEROLIMUS, RAD001, | I.T.M.O. - ITALIAN TRIALS IN MEDICAL ONCOLOGY | Patients with neuroendocrine tumours | | | | |
|
2009-016640-39: Everolimus added to long acting octreotide as a volume reducing treatment of polycystic livers. |
|
|
| Ongoing | 2 | 44 | Europe | Everolimus, octreotide LAR, RAD001, unknown, | Radboud University Nijmegen Medical Centre | Isolated polycystic liver disease | | | | |
2014-000256-28: A study to assess the use of Octreotide in the prevention or reduction of diarrhoea associated with lapatinib and capecitabine treatment in patients with metastatic breast cancer. |
|
|
| Ongoing | 2 | 40 | Europe | Sandostatin® LAR®, Sandostatin, N/A, Sandostatin® LAR® (10 mg, 20 mg or 30 mg powder and solvent for suspension for injection), Sandostatin (0.05mg/ml, 0.1 mg/ml, 0.5 mg/ml Ampoules and Multidose Vial 1 mg/5 ml), Tyverb, Sandostatin® LAR® (10 mg, 20 mg or 30 mg powder and solvent for suspension for injection), Sandostatin (0.05mg/ml, 0.1 mg/ml, 0.5 mg/ml Ampoules and Multidose Vial 1 mg/5 ml), Tyverb | GlaxoSmithKline research & Development, GlaxoSmithKline R&D | Diarrhoea associated with treatment with lapatinib and capecitabine for metastatic breast cancer | | | | |
| Not yet recruiting | 2 | 34 | Europe | SANDOSTATINA, OCTEOTRIDE, Powder and solvent for suspension for injection, SANDOSTATINA - LAR 30 MG/2.5 ML POLVERE E SOLVENTE PER SOSPENSIONE INIETTABILE FLACONE POLVERE + SIRINGA PRERIEMPITA 2.5 ML + 2 AGHI | ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE, Novartis | patient with neuroendocrine tumors pazienti con tumore neuroendocrino, patient with neuroendocrine tumors pazienti con tumore neuroendocrino, Diseases [C] - Cancer [C04] | | | | |
Lu-Ca-S, NCT02736448: 177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors |
|
|
| Active, not recruiting | 2 | 35 | Europe | Capecitabine, Lu-PRRT, SS-LAR | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | Gastro-entero-pancreatic Neuroendocrine Tumors | 08/19 | 06/21 | | |
2019-001200-38: Is it possible to improve the nutritional recovery with a medicine called Sandostatin after surgery for esophageal or gastric cancer? |
|
|
| Not yet recruiting | 2 | 172 | Europe | Powder and solvent for suspension for injection, Sandostatin LAR 10mg | Karolinska Universitetssjukhuset, Karolinska Universitetssjukhuset, FoU-enheten PO övre buk B75 | Undesired weight loss after operation for esophageal or gastric cancer, Undesired weight loss after operation for esophageal or gastric cancer, Body processes [G] - Metabolic Phenomena [G03] | | | | |
2020-004075-41: Research on the effectiveness of octreotide in Gastric Antral Vascular Ectasia (GAVE) in patients with anemia. Onderzoek naar de effectiviteit van octreotide in Gastric Antral Vascular Ectasia (GAVE) bij patiënten met bloedarmoede. |
|
|
| Ongoing | 2 | 12 | Europe | Sandostatin LAR, Emulsion for injection, Sandostatin LAR | Radboudumc, Radboudumc | Gastric Antral Vascular Ectasia (also known as watermelon stomach) Gastric Antral Vascular Ectasia (ook wel bekend als watermeloenmaag), Gastric Antral Vascular Ectasia (also known as watermelon stomach) Gastric Antral Vascular Ectasia (ook wel bekend als watermeloenmaag), Body processes [G] - Digestive System and Oral Physiological Phenomena [G10] | | | | |
MetNET1, NCT02294006: Activity and Safety of Everolimus+Octreotide LAR+Metformin in Advanced Pancreatic Well-differentiated NETs |
|
|
| Active, not recruiting | 2 | 26 | Europe | Everolimus plus Octreotide LAR plus Metformin | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Well Differentiated Pancreatic Endocrine Tumor | 06/21 | 10/21 | | |
OTIS, NCT04871204: Octreotide Treatment to Improve Nutritional Recovery After Surgery for Patients With Esophageal or Gastric Cancer |
|
|
| Recruiting | 2 | 152 | Europe | Octreotide Injection | Fredrik Klevebro, Karolinska University Hospital | Esophageal Cancer, Gastric Cancer | 06/24 | 12/24 | | |
ChiCTR2100048509: A prospective, single-arm, open-label study to evaluate the efficacy and safety of Surufatinib in combination with Octreotide LAR as first line treatment in G1-G2 Gastroenteropancreatic Neuroendocrine Tumors patients |
|
|
| Not yet recruiting | 2 | 33 | | Surufatinib+Octreotide LAR | Jiangsu Cancer Hospital; Jiangsu Cancer Hospital, self-funded | Neuroendocrine Tumors | | | | |
| Not yet recruiting | 2 | 135 | NA | Local standard of Care, Hydroxycarbamide, Bevacizumab, Sunitinib, Octreotide (Sandostatin LAR), Everolimus, No active treatment (observation with regular follow-up and best supportive care), 177Lu-DOTATATE, ¹⁷⁷Lu-DOTA0-TATE, Lutathera®, Lu oxodotreotide | European Organisation for Research and Treatment of Cancer - EORTC, Novartis | Recurrent Meningioma | 04/27 | 12/28 | | |
NCT03879694: Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors |
|
|
| Recruiting | 1 | 14 | US | Incomplete Freund's Adjuvant, Freund's Incomplete Adjuvant, IFA, ISA-51, Montanide ISA 51, Montanide ISA-51, Octreotide Acetate, D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hyroxymethyl)propyl]-L-cysteinamide, Cyclic (2->7)-disulfide, Acetate (Salt), Longastatin, Longastatina, Samilstin, Sandostatin, Sandostatin Lar Depot, Sandostatina, Sandostatine, SMS 201-995, SMS 201-995 AC, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin, SVN53-67/M57-KLH Peptide Vaccine | Roswell Park Cancer Institute, NeuroEndocrine Tumor Research Foundation (NETRF) | Lung Atypical Carcinoid Tumor, Lung Typical Carcinoid Tumor, Metastatic Pancreatic Neuroendocrine Tumor | 12/24 | 12/25 | | |
OXTEND-01, NCT05364944: A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) |
|
|
| Active, not recruiting | 1 | 30 | Europe, RoW | Debio 4126, Sandostatin LAR, Octreotide acetate, Somatuline ATG, Lanreotide acetate | Debiopharm International SA | Acromegaly, GEP-NET | 11/24 | 12/24 | | |
NCT06080204: Real-world Study on Adjuvant Octreotide Therapy in pNETs |
|
|
| Completed | N/A | 411 | NA | Octreotide LAR, Sandostatin | Changhai Hospital | Pancreatic Neuroendocrine Tumor G2 | 04/20 | 04/20 | | |
ChiCTR1800018070: Clinical study of rehoci combined with long-acting octreotide in reducing the risk of rebleeding in patients with cirrhosis and portal hypertension |
|
|
| Not yet recruiting | N/A | 80 | | placebo ;rifaximin ;long acting octreotide ;rifaximin+long acting octreotide | Shanghai Jiao Tong University Affiliated Sixth People's Hospital; Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Self financing | portal hypertension | | | | |
| Recruiting | N/A | 70 | Europe | Octreotide, Octreotide LAR | Mario Negri Institute for Pharmacological Research | Autosomal Dominant Polycystic Kidney | 12/24 | 12/24 | | |